ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 173 filers reported holding ASCENDIS PHARMA A/S in Q2 2021. The put-call ratio across all filers is 4.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $56,453,121 | +9.4% | 602,874 | +4.2% | 0.02% | +14.3% |
Q2 2023 | $51,621,040 | -6.5% | 578,387 | +12.3% | 0.02% | -12.5% |
Q1 2023 | $55,224,519 | -7.7% | 515,058 | +5.1% | 0.02% | -11.1% |
Q4 2022 | $59,837,105 | -9.4% | 489,946 | -23.4% | 0.03% | -15.6% |
Q3 2022 | $66,074,000 | +3.9% | 639,876 | -6.4% | 0.03% | +10.3% |
Q2 2022 | $63,566,000 | -23.6% | 683,796 | -3.5% | 0.03% | -9.4% |
Q1 2022 | $83,194,000 | -12.9% | 708,881 | -0.2% | 0.03% | -5.9% |
Q4 2021 | $95,537,000 | +7.4% | 710,152 | +27.3% | 0.03% | -2.9% |
Q3 2021 | $88,929,000 | +16.1% | 557,931 | -4.2% | 0.04% | +12.9% |
Q2 2021 | $76,614,000 | +24.0% | 582,398 | +21.5% | 0.03% | +14.8% |
Q1 2021 | $61,778,000 | -19.9% | 479,342 | +3.6% | 0.03% | -25.0% |
Q4 2020 | $77,141,000 | +6.7% | 462,533 | -1.3% | 0.04% | -7.7% |
Q3 2020 | $72,299,000 | +9.4% | 468,501 | +4.8% | 0.04% | 0.0% |
Q2 2020 | $66,116,000 | +16.7% | 447,034 | -11.2% | 0.04% | -4.9% |
Q1 2020 | $56,672,000 | -24.2% | 503,257 | -6.3% | 0.04% | -2.4% |
Q4 2019 | $74,719,000 | +45.0% | 537,086 | +0.4% | 0.04% | +31.2% |
Q3 2019 | $51,545,000 | -11.1% | 535,146 | +6.3% | 0.03% | -11.1% |
Q2 2019 | $57,967,000 | -19.4% | 503,405 | -17.6% | 0.04% | -23.4% |
Q1 2019 | $71,898,000 | +67.1% | 610,854 | -11.0% | 0.05% | +46.9% |
Q4 2018 | $43,018,000 | -15.0% | 686,644 | -3.9% | 0.03% | -3.0% |
Q3 2018 | $50,620,000 | +9.4% | 714,366 | +2.7% | 0.03% | +3.1% |
Q2 2018 | $46,253,000 | -3.6% | 695,327 | -5.2% | 0.03% | -8.6% |
Q1 2018 | $47,963,000 | +2055.6% | 733,383 | +1220.5% | 0.04% | +1650.0% |
Q4 2017 | $2,225,000 | +104.5% | 55,540 | +85.1% | 0.00% | +100.0% |
Q3 2017 | $1,088,000 | – | 30,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |